| Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40139004无 PMCID | 2025-May-02 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306.Eur J Cancer | PMID 40179821无 PMCID | 2025-May-02 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study.Eur J Cancer | PMID 40198940无 PMCID | 2025-May-02 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS.Rheumatology (Oxford) | PMID 39437003PMC12048074 | 2025-May-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer.Clin Cancer Res | PMID 39656603PMC12045734 | 2025-May-01 | 0.90 | Eligible trials must include a drug-containing intervention. This report analyzes a phase III randomized trial (NRG/RTOG 9512) but the intervention was radiation fractionation (non-drug). It is a secondary biomarker analysis, not a primary report of a drug intervention trial. | 待处理 |
| Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.J Natl Cancer Inst疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39656951PMC12058262 | 2025-May-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Brief Report: Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials.J Acquir Immune Defic Syndr | PMID 39748155PMC11970612 | 2025-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies.J Rheumatol | PMID 39892885无 PMCID | 2025-May-01 | 0.95 | The record describes a Phase III randomized trial of a drug (bimekizumab) in psoriatic arthritis, not an oncology condition. The primary endpoints are patient-reported outcomes and work productivity, not the required time-to-event efficacy endpoints (OS, PFS, etc.). | 待处理 |
| Tight Control and Radiological Progression: The Radiographic Outcomes of the TICOPA Study.J Rheumatol | PMID 39892892无 PMCID | 2025-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.Clin Cancer Res疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1.:AI 判定为 other;Figure 2.:非 KM 图;Figure 3.:AI 判定为 other;Figure 4.:生活质量量表图;Figure 5.:非 KM 图。 | PMID 40019493PMC12010963 | 2025-May-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea: Two Phase 3 Randomized Clinical Trials.JAMA Dermatol | PMID 40042869PMC11883608 | 2025-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials.JAMA Neurol | PMID 40063015PMC11894547 | 2025-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Precision Exercise Effect on Fatigue and Function in Lung Cancer Surgery: A Randomized Clinical Trial.JAMA Surg | PMID 40072448PMC11904799 | 2025-May-01 | 0.95 | The trial is an oncology Phase III randomized controlled trial with primary results, but the intervention is a non-drug exercise program and the primary endpoints are physical function and fatigue (not time-to-event efficacy endpoints like OS, PFS, DFS, etc.). | 待处理 |
| Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials.Diabetes Care | PMID 40100982PMC12034897 | 2025-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Randomized Clinical Trial of Prolonged Exposure Therapy With and Without Topiramate for Comorbid PTSD and Alcohol Use Disorder.Am J Psychiatry | PMID 40103353PMC13288295 | 2025-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial.JAMA Neurol | PMID 40126464PMC11933997 | 2025-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype.N Engl J Med | PMID 40305712无 PMCID | 2025-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial.JAMA Netw Open | PMID 40332939PMC12059972 | 2025-May-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Combining Exercise Training and Testosterone Therapy in Older Women After Hip Fracture: The STEP-HI Randomized Clinical Trial.JAMA Netw Open | PMID 40372752PMC12082367 | 2025-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Becoming attack-free further improves health-related quality of life in patients with hereditary angioedema receiving garadacimab.Allergy Asthma Proc | PMID 40380356无 PMCID | 2025-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tocilizumab Monotherapy or Combined With Methotrexate for Rheumatoid Arthritis: A Randomized Clinical Trial.JAMA Netw Open | PMID 40388166PMC12090025 | 2025-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pharmacodynamic Effect of Different Dosage Regimes of Oseltamivir in Severe Influenza Patients Requiring Mechanical Ventilation: A Multicentre Randomised Controlled Trial.Influenza Other Respir Viruses | PMID 40384328PMC12086322 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of topical minocycline foam (FMX101 4%) in treatment of Chinese subjects with moderate-to-severe facial acne vulgaris: A phase 3, multi-centre, randomized, double-blind, vehicle-controlled study.J Eur Acad Dermatol Venereol | PMID 38948962无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase-IT on cognitive function in siblings with neuronopathic mucopolysaccharidosis II.J Inherit Metab Dis | PMID 39252529PMC12041835 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism.Andrology | PMID 39252657PMC12006877 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial.Clin Res Cardiol | PMID 39297940PMC12058928 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials.Clin Gastroenterol Hepatol | PMID 39326583无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial.Allergy | PMID 39450683无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Anatomic Outcomes with Faricimab vs Aflibercept in Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular Age-related Macular Degeneration.Ophthalmology | PMID 39617060无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Exploring Opioid Use Disorder Outcomes by Quantitative Urinalysis: Post Hoc Analysis of a Phase 3 Randomized Clinical Trial.J Addict Med | PMID 39629836无 PMCID | 2025 May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial.Lancet Infect Dis | PMID 39647494无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Procalcitonin-guided use of antibiotic in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: a randomized clinical trial.Clin Microbiol Infect | PMID 39662822无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图。 | PMID 39671533PMC12054981 | 2025-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| A relook at the relevance of thyroid stimulating hormone and thyroid autoimmunity for pregnancy outcomes: Analyses of randomized control trials data from Pregnancy in Polycystic Ovary Syndrome and Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation.Fertil Steril | PMID 39672366PMC12045735 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in children aged 10-12 years: phase III randomized trial complementary analysis of immune persistence 3-6 years after priming.Pediatr Res | PMID 39672823PMC12122353 | 2025-May | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Effect of Digoxin vs Beta-Blockers on Left Atrial Strain for Heart Rate-Controlled Atrial Fibrillation: The DIGOBET-AF Randomized Clinical Trial.Am J Cardiovasc Drugs | PMID 39725795无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.J Clin Oncol | PMID 39772884PMC12054979 | 2025-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial.Eur J Haematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39777934无 PMCID | 2025-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Albendazole-ivermectin co-formulation for the treatment of Trichuris trichiura and other soil-transmitted helminths: a randomised phase 2/3 trial.Lancet Infect Dis | PMID 39805305无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis.Clin Exp Rheumatol | PMID 39808286无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients.Clin Exp Rheumatol | PMID 39808288无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39814199无 PMCID | 2025-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis.Eur J Heart Fail | PMID 39823276无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study.Lancet Infect Dis | PMID 39824198无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Digital Profiling of Immune Biomarkers in Breast Cancer: Relation to Anthracycline Benefit.Mod Pathol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39863112无 PMCID | 2025-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.J Clin Oncol | PMID 39879577PMC12054980 | 2025-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials.J Clin Oncol入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 39903903PMC12054978 | 2025-May | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Radiotherapy quality assurance for the PEACE 1 trial: An individual case review analysis.Radiother Oncol | PMID 39924002无 PMCID | 2025-May | 0.85 | The record describes results from a randomized phase-III oncology trial, but the reported results are solely about radiotherapy quality assurance (compliance rates for dose and volume parameters). It does not present any time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or associated statistics (Kaplan-Meier curves, hazard ratios). | 待处理 |
| Using methods to extend inferences to specific target populations to improve the precision of subgroup analyses.J Clin EpidemiolAI 判定该论文不进入自动 KM 提取:The record is a methodological study that re-analyzes data from a Phase III RCT to demonstrate statistical methods, not a new clinical trial report. | PMID 39924128PMC13192252 | 2025-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Characterization of the effect of naltrexone/bupropion on body composition.Diabetes Obes Metab | PMID 39927409PMC11965020 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |